Medizinische Klinik B, Klinikum Ludwigshafen, Bremserstraße 79, 67063, Ludwigshafen, Germany.
Institut für Herzinfarktforschung, Ludwigshafen, Germany.
Clin Res Cardiol. 2018 Dec;107(12):1160-1169. doi: 10.1007/s00392-018-1290-7. Epub 2018 Jun 12.
Interventional closure of paravalvular leaks (PVL) by plug implantation has emerged as an alternative to surgical correction, which is associated with high mortality rates for re-operation. To date, data on procedural efficacy and clinical outcome after transcatheter closure is sparse. We present our experience with interventional PVL closure at our site.
From 08/2014 to 10/2016 ten patients (three women, seven men) at high surgical risk for repeat surgery underwent interventional PVL closure for severe paravalvular regurgitation (PVR) in 14 procedures at our site. Nine procedures (64%) were performed for mitral PVLs, five procedures were performed for aortic PVLs (36%). Mean age of the population treated was 70 ± 8.6 years and mean log. Euro-Score I was 27.4 ± 14.9%. All patients were treated by implantation of Amplatzer Vascular Plug III occluders. All aortic PVLs were treated using a retrograde transfemoral access, mitral PVLs were treated using either a transseptal (8/9) or transapical access (1/9) under 3-dimensional transesophageal echocardiographic and fluoroscopic guidance. Indication for PVL closure was the presence of severe heart failure symptoms in all patients (NYHA class III/IV, n = 14) and additional mechanical hemolytic anemia (n = 5) with a need for transfusion. Interventional closure of PVL was completely successful in 12 procedures (85%), partially successful in one procedure due to inability to cross the defect with a wire (7.5%) and failed in one of 14 procedures due to inability of plug deployment in a very large defect (7.5%). One patient in a critical clinical condition died within 24 h after procedure due to progressive cardiogenic shock after procedural failure and refusal of a surgical treatment by cardiac surgeons. After interventional treatment clinical success with improvement in NYHA functional class or hemolysis was achieved in 93% (13/14). Median NYHA class improved significantly from 4 prior to procedure to 2 after PVL closure (p = 0.0005). Severe PVR was significantly reduced to mild in six patients and to moderate in three patients after procedure (p = 0.001). Complications included one hemothorax after transapical access and one pseudoaneurysm after transfemoral arterial access. In-hospital mortality rate was 20% (2/10) in this high-risk population. After hospital discharge no death occurred during 30-day follow-up, one patient died during 1-year follow-up after PVL closure.
In this single-center series interventional PVL closure appears promising for patients at high surgical risk with symptomatic paravalvular regurgitation. Gaining experience in interventional PVL closure at specialized sites will further improve safety and efficacy of this relatively new treatment option. All patients should be treated within large clinical registries to gain more data on mid- and long-term efficacy of transcatheter PVL closure.
通过植入塞子进行经导管瓣周漏(PVL)封堵已成为手术修复的替代方法,后者与再次手术的高死亡率相关。迄今为止,关于经导管封堵后程序疗效和临床结果的数据很少。我们介绍了我们在该部位进行经导管 PVL 封堵的经验。
从 2014 年 8 月至 2016 年 10 月,我们在该部位对 10 名高手术风险的患者(3 名女性,7 名男性)进行了 14 次介入性 PVL 封堵术,用于治疗严重瓣周反流(PVR)。9 例(64%)为二尖瓣 PVL,5 例(36%)为主动脉 PVL。治疗人群的平均年龄为 70±8.6 岁,平均 log。欧洲评分 I 为 27.4±14.9%。所有患者均采用 Amplatzer 血管塞 III 封堵器进行治疗。所有主动脉 PVL 均采用逆行经股动脉入路治疗,二尖瓣 PVL 采用经房间隔(8/9)或经心尖(1/9)入路,在 3 维经食管超声心动图和透视引导下进行。PVL 封堵的指征均为所有患者(NYHA 分级 III/IV,n=14)均存在严重心力衰竭症状和(n=5)需要输血的其他机械性溶血性贫血。12 例(85%)PVL 封堵完全成功,1 例(7.5%)因无法用导丝穿过缺损而部分成功,1 例(7.5%)因非常大的缺损无法放置塞子而失败在 14 例中。一名患者在程序失败后出现进行性心源性休克并拒绝心脏外科手术治疗,在 24 小时内处于危急临床状况下死亡。介入治疗后,93%(13/14)的患者在改善 NYHA 功能分级或溶血方面取得了临床成功。术后 NYHA 分级中位数从术前的 4 级显著改善至 2 级(p=0.0005)。术后 6 例严重 PVR 显著减轻至轻度,3 例减轻至中度(p=0.001)。并发症包括经心尖入路后 1 例血胸和经股动脉入路后 1 例假性动脉瘤。在该高危人群中,住院死亡率为 20%(2/10)。出院后 30 天随访期间无死亡发生,1 例患者在 PVL 封堵后 1 年随访期间死亡。
在这个单中心系列中,对于有症状的瓣周反流且手术风险高的患者,经导管 PVL 封堵似乎很有希望。在专门的治疗中心获得经导管 PVL 封堵的经验将进一步提高这种相对较新的治疗选择的安全性和有效性。所有患者均应在大型临床登记处接受治疗,以获得更多关于经导管 PVL 封堵的中期和长期疗效的数据。